By Budi Oetomo Narendra 
For a significant number of breast cancer survivors, the arduous journey through cancer treatment often leaves behind a persistent and debilitating legacy: cognitive impairment, commonly known as "chemo brain" or "brain fog." This insidious condition, characterized by memory lapses, difficulty concentrating, and profound, persistent exhaustion, can interfere profoundly with everyday life, sometimes for years after cancer care concludes. In a significant development offering a beacon of hope, researchers at the UCLA Health Jonsson Comprehensive Cancer Center have now presented promising early evidence suggesting that a dietary supplement containing a naturally occurring molecule could help relieve these challenging symptoms.
The molecule at the heart of this breakthrough is oxaloacetate, an essential component already present within the human body, playing a crucial role in how cells generate energy. In a small but impactful clinical trial, breast cancer survivors who incorporated the oxaloacetate supplement into their daily regimen for eight weeks reported noticeable and significant improvements in their thinking abilities, memory recall, concentration, and, crucially, a reduction in their pervasive fatigue. These findings, while preliminary, point towards a potentially new and much-needed therapeutic avenue for a problem that has long eluded effective treatment.
The Lingering Shadow of Cancer Treatment: Understanding Cancer-Related Cognitive Impairment
The journey through cancer treatment is often a battle fought on multiple fronts, and while survival rates continue to improve for many cancers, the long-term quality of life for survivors remains a critical area of focus. Among the most vexing post-treatment challenges is cancer-related cognitive impairment (CRCI). This condition is not merely a temporary haze but a persistent and often distressing decline in cognitive function that can profoundly impact a survivor’s ability to return to work, manage daily tasks, maintain social connections, and ultimately, reclaim their pre-cancer life.
Estimates suggest that roughly 15% to 25% of individuals who survive breast cancer experience ongoing problems with memory, concentration, information processing speed, or other executive functions long after their diagnosis and treatment. The term "chemo brain," while widely used, is somewhat misleading. While chemotherapy is a significant contributor, scientists increasingly recognize that CRCI is a complex phenomenon arising from several overlapping processes. The cancer itself, the systemic inflammation it induces, the effects of chemotherapy and radiation, endocrine therapy, hormonal fluctuations, psychological stress, sleep disturbances, and other biological and behavioral influences may all contribute to this multi-faceted impairment. This complexity has historically made CRCI particularly difficult to diagnose comprehensively and, more importantly, to treat effectively. Patients often report feeling dismissed or misunderstood, adding to their distress. The economic burden, though hard to quantify precisely, includes lost productivity, decreased earning potential, and increased healthcare utilization for managing related symptoms.
Unraveling the Mechanisms of "Brain Fog": A Biological Perspective
Because the underlying causes of CRCI are intricate and multi-layered, and effective treatments remain limited, researchers have been intensely investigating ways to address the fundamental biological changes that disrupt normal brain function in cancer survivors. One particularly fertile area of inquiry involves the intricate relationship between inflammation, brain chemistry, and cellular energy production.
Inflammation, often a byproduct of cancer and its aggressive treatments, can have deleterious effects on brain function. It can interfere with glutamate signaling, a critical neurotransmitter pathway essential for communication between nerve cells, memory formation, and learning. Furthermore, inflammatory processes can disturb the delicate machinery within brain cells that allows them to produce and utilize energy efficiently, primarily through mitochondrial function. When brain cells struggle to generate and manage energy, their ability to perform complex cognitive tasks is compromised, leading to difficulties with thinking, processing information, and the pervasive mental exhaustion that survivors describe. This disruption in cellular energetics and neurochemical balance is thought to be a key driver of CRCI symptoms.
It was this understanding of CRCI’s biological underpinnings that drew the UCLA team’s attention to oxaloacetate. This molecule is not a foreign substance; it is a vital intermediate in the Krebs cycle (also known as the citric acid cycle), the central metabolic pathway that cells use to generate energy (ATP) from carbohydrates, fats, and proteins. Beyond its role in energy production, oxaloacetate also plays a part in regulating glutamate levels in the brain. Given its dual involvement in cellular energy metabolism and neurochemical balance, the researchers hypothesized that supplementing with oxaloacetate might help mitigate the cognitive symptoms and profound fatigue experienced by cancer survivors by restoring some level of cellular homeostasis.
The UCLA Health Pilot Study: Testing Oxaloacetate for Brain Fog and Fatigue
To investigate this compelling hypothesis, the UCLA researchers embarked on a phase II clinical trial, a crucial step in testing the safety and initial efficacy of a new intervention. The trial involved 18 women, all of whom had been diagnosed with early-stage breast cancer between one and five years prior to enrollment. A critical criterion for participation was that all subjects were experiencing substantial, self-reported cognitive difficulties when they entered the study, highlighting the real-world impact of CRCI.
The participants, approximately 50 years old on average, represented a demographic frequently affected by breast cancer. The majority (over 80%) had undergone chemotherapy, a known risk factor for CRCI, and nearly 90% were still receiving endocrine therapy during the trial, further underscoring the ongoing nature of their post-treatment challenges. This patient profile provided a relevant and representative group to evaluate the potential benefits of oxaloacetate.
Each participant was meticulously instructed to take 500 milligrams of oxaloacetate twice daily for a period of eight weeks. The researchers employed a comprehensive approach to track changes in cognitive symptoms, combining both subjective and objective measures. Participants completed detailed questionnaires designed to capture their perceived cognitive impairment, memory function, attention, and concentration. Alongside these self-reported measures, standardized neuropsychological tests were administered to objectively evaluate various cognitive domains, including memory, processing speed, and executive function. Executive function, a critical set of mental abilities, encompasses skills needed to organize activities, maintain focus, plan effectively, and manage complex tasks—all areas frequently compromised in CRCI. The study also extended its scope to examine other quality-of-life indicators, including fatigue levels (both physical and mental), sleep quality, anxiety, depression, and overall physical and mental well-being. Throughout the entire treatment period, the research team diligently monitored participants for any possible side effects, prioritizing patient safety.
Encouraging Results: Quantifying Improvement After Eight Weeks
Of the 18 women initially enrolled in the study, 16 successfully completed the full eight weeks of oxaloacetate supplementation, a high completion rate indicating good tolerability. The findings, published in the esteemed journal JCO Oncology Advances, revealed a highly encouraging trend: every single participant who finished the treatment reported significant and clinically meaningful improvements in her cognitive symptoms.
The changes were particularly striking on the study’s main measure of perceived cognitive impairment, which utilizes a standardized questionnaire to assess the severity of "brain fog" from the patient’s perspective. Before commencing treatment, the participants had an average score of 29.1, indicative of significant impairment. After eight weeks of oxaloacetate supplementation, that average score climbed dramatically to 55.5. This notable increase placed the group well within the range considered normal rather than impaired, suggesting a profound subjective improvement in their daily cognitive function. Notably, signs of improvement were already apparent after just four weeks of treatment, and the benefits reported by participants generally became more pronounced and sustained as the treatment period continued, suggesting a cumulative effect.
The positive outcomes extended beyond improvements in memory and concentration. Participants also reported significantly less fatigue, a debilitating symptom often intertwined with cognitive issues. This included a substantial reduction in the mental exhaustion that can make even routine everyday activities feel insurmountable. Furthermore, patients described meaningful improvements in their ability to function physically, indicating a broader positive impact on their overall quality of life and energy levels.
Crucially, the subjective reports were corroborated by objective data from standardized cognitive testing. Researchers observed measurable improvements in processing speed—how quickly individuals can take in and respond to information—and executive function, including tasks requiring planning, attention, and mental flexibility. These objective improvements suggest that some fundamental aspects of thinking performance may have genuinely improved alongside the participants’ perceptions of their symptoms, lending greater weight to the findings. Dr. Patricia Ganz, the study’s first author and a distinguished professor of medicine at UCLA’s David Geffen School of Medicine and UCLA Fielding School of Public Health, articulated the significance of these findings: "Cancer-related cognitive impairment can persist long after treatment ends and can have a significant impact on a person’s daily life, yet we still have very few effective treatments for it. These early findings give us a strong reason to continue studying oxaloacetate as a potential approach for managing cognitive problems after breast cancer treatment."
Understanding the Caveats: Preliminary Nature and Future Steps
While the results from this phase II clinical trial are undoubtedly promising and generate considerable enthusiasm within the oncology and survivorship communities, the scientists involved were quick to emphasize their preliminary nature. Oxaloacetate was generally well tolerated throughout the eight-week study period, which is a critical factor for any potential therapeutic agent. The most frequently reported side effects involved the digestive system, including mild indigestion, bloating, constipation, diarrhea, and nausea. Two women did stop taking the supplement due to these gastrointestinal symptoms, but no serious adverse events were recorded, indicating a favorable safety profile in this small cohort.
Despite the encouraging improvements in both subjective and objective measures, the researchers cautioned against drawing firm, definitive conclusions about the supplement’s effectiveness at this stage. The primary limitation of this initial trial is its small sample size (18 participants) and, crucially, the absence of a placebo group or another comparison group. Without a control group receiving an inert substance, it is impossible to definitively determine whether oxaloacetate itself was solely responsible for the observed improvements, or if other factors, such as the placebo effect, natural fluctuations in symptoms, or increased attention from the study team, played a role. This is a standard and necessary caution in early-phase clinical research.
The Path Forward: Larger Trials and Deeper Insights
To build upon these initial, compelling findings and address the limitations of the pilot study, the UCLA team is already preparing for the next critical phase of research. They are organizing a randomized, placebo-controlled phase IIb clinical trial, a more robust study design considered the gold standard for evaluating efficacy. This larger trial will involve a greater number of breast cancer survivors specifically experiencing cancer-related cognitive impairment. The study is anticipated to begin enrolling participants in late 2026. By rigorously comparing the effects of oxaloacetate against a placebo, the researchers aim to definitively establish whether the supplement produces measurable benefits that are genuinely attributable to the active molecule, beyond any effects that might occur without active treatment. This next step is essential for solidifying the scientific evidence base.
Beyond human clinical trials, the investigators are also conducting parallel preclinical research in mice. These animal studies are designed to better understand the fundamental mechanisms by which oxaloacetate affects the body and, more specifically, the brain. These experiments include a placebo-controlled study examining whether the molecule produces similar improvements in cognitive function, fatigue, and physical activity in animal models. Such mechanistic studies are vital for elucidating how oxaloacetate interacts with biological pathways implicated in CRCI, potentially identifying biomarkers of response, and optimizing future treatment strategies. This comprehensive approach, spanning both human and animal research, reflects the scientific rigor applied to developing novel therapies.
The groundbreaking research received partial financial support from two highly respected organizations: the Breast Cancer Research Foundation and the National Cancer Institute, underscoring the significance and potential impact of this work within the broader cancer research landscape. The study’s authors, in addition to Dr. Ganz, included Kathleen Van Dyk, PhD, Catherine M. Crespi, PhD, Laura Petersen, MS, Mina Sedrak, MD, MS, and Julienne Bower, PhD, all affiliated with UCLA, highlighting a collaborative effort across multiple disciplines.
Broader Implications for Cancer Survivorship and Future Research
The potential implications of these early findings for the field of cancer survivorship are profound. If larger, placebo-controlled trials confirm the efficacy of oxaloacetate, it could represent a significant therapeutic advancement for millions of cancer survivors worldwide who grapple with the debilitating effects of "chemo brain." The fact that oxaloacetate is a naturally occurring molecule already present in the human body, with a generally favorable safety profile in this initial study, makes it a particularly attractive candidate for further investigation. It could offer a non-pharmacological, biologically-based intervention that addresses fundamental cellular and neurological disruptions, rather than merely managing symptoms.
This research also underscores the growing recognition within oncology that holistic care for cancer patients extends far beyond eradicating the disease. Addressing the long-term side effects that impact quality of life, such as cognitive impairment and fatigue, is becoming an increasingly central tenet of comprehensive cancer care. The quest for effective treatments for CRCI is not just about improving memory scores; it’s about enabling survivors to fully re-engage with their lives, careers, and families, restoring a sense of normalcy and well-being that cancer often steals. As Dr. Ganz aptly points out, the lack of effective treatments for CRCI represents a significant unmet medical need. This UCLA study, while a modest first step, offers a tangible glimmer of hope that this long-standing challenge may one day be overcome, paving the way for a future where cancer survivorship means not just living longer, but living better. The scientific community and cancer survivors alike will eagerly await the results of the forthcoming larger trials, hoping that oxaloacetate fulfills its early promise.
